JP Morgan Chase
HRMY icon

JP Morgan Chase’s Harmony Biosciences HRMY Stock Holding History

JP Morgan Chase’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,600
Closed -$188K – 7536
2024
Q1 		$188K Buy
+5,600
New +$180K ﹤0.01% 5389

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase's HRMY Position: Q2 2026 in Review

JP Morgan Chase reduced its Harmony Biosciences (HRMY) stake by 38% in Q2 2026, selling an estimated $9.76M and leaving 514,085 shares worth $18.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2301.

JP Morgan Chase first reported a position in HRMY in Q3 2020 and has held it in 24 quarters since. The position peaked at $22.2M in Q1 2026. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • JP Morgan Chase held 514,085 shares of Harmony Biosciences worth $18.2M as of Q2 2026.
  • JP Morgan Chase sold 309,428 Harmony Biosciences shares in Q2 2026, an estimated $9.76M.
  • Harmony Biosciences made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2301 holding.
  • JP Morgan Chase first reported a position in Harmony Biosciences in Q3 2020 and has held it in 24 quarters since.
  • JP Morgan Chase's Harmony Biosciences position peaked at $22.2M in Q1 2026.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.